EP0595970A4 - Verbesserter impfstoff. - Google Patents

Verbesserter impfstoff.

Info

Publication number
EP0595970A4
EP0595970A4 EP92916278A EP92916278A EP0595970A4 EP 0595970 A4 EP0595970 A4 EP 0595970A4 EP 92916278 A EP92916278 A EP 92916278A EP 92916278 A EP92916278 A EP 92916278A EP 0595970 A4 EP0595970 A4 EP 0595970A4
Authority
EP
European Patent Office
Prior art keywords
improved vaccine
vaccine
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92916278A
Other languages
English (en)
French (fr)
Other versions
EP0595970A1 (de
Inventor
Peter John Walker
Christophe Jean Prehaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organization CSIRO
Original Assignee
Commonwealth Scientific and Industrial Research Organization CSIRO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commonwealth Scientific and Industrial Research Organization CSIRO filed Critical Commonwealth Scientific and Industrial Research Organization CSIRO
Publication of EP0595970A1 publication Critical patent/EP0595970A1/de
Publication of EP0595970A4 publication Critical patent/EP0595970A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP92916278A 1991-07-17 1992-07-17 Verbesserter impfstoff. Withdrawn EP0595970A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU7258/91 1991-07-17
AUPK725891 1991-07-17
PCT/AU1992/000363 WO1993001833A1 (en) 1991-07-17 1992-07-17 Improved vaccine

Publications (2)

Publication Number Publication Date
EP0595970A1 EP0595970A1 (de) 1994-05-11
EP0595970A4 true EP0595970A4 (de) 1995-05-31

Family

ID=3775548

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92916278A Withdrawn EP0595970A4 (de) 1991-07-17 1992-07-17 Verbesserter impfstoff.

Country Status (5)

Country Link
EP (1) EP0595970A4 (de)
JP (1) JPH06509228A (de)
CA (1) CA2113572A1 (de)
NZ (1) NZ243611A (de)
WO (1) WO1993001833A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA937164B (en) * 1992-09-28 1994-05-23 Commw Scient Ind Res Org Delivery system
US6818209B1 (en) 1998-05-22 2004-11-16 Oxford Biomedica (Uk) Limited Retroviral delivery system
ATE435297T1 (de) * 1998-05-22 2009-07-15 Oxford Biomedica Ltd Retrovirales verabreichungssystem
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
EP1219705B1 (de) * 2000-12-29 2007-11-28 Evotec AG Virus-ähnliche Partikel, ihre Herstellung und ihre Verwendung beim pharmazeutischen Screening und funktionelle Genomanwendungen
WO2008124636A1 (en) 2007-04-04 2008-10-16 Weatherford/Lamb, Inc. Apparatus and methods of milling a restricted casing shoe
TWI526539B (zh) 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
MX350421B (es) * 2011-06-13 2017-09-06 Medicago Inc Producción de partículas tipo virus de la rabia en plantas.
CN102533680B (zh) * 2011-06-24 2014-03-26 武汉生物制品研究所有限责任公司 狂犬病毒病毒样颗粒及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0508809A1 (de) * 1991-04-10 1992-10-14 British Bio-Technology Limited Fett enthaltende proteinhaltige Partikel
WO1992017589A1 (es) * 1991-03-26 1992-10-15 Ercros S.A. Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino
WO1992017205A1 (es) * 1991-03-26 1992-10-15 Ercros S.A. Procedimiento para la produccion de una vacuna subunidad contra el parvovirus canino y otros virus relacionados
WO1992019267A1 (en) * 1991-05-08 1992-11-12 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU601378B2 (en) * 1985-10-04 1990-09-13 Pharmacia & Upjohn Company Pseudorabies virus protein
US5037742A (en) * 1986-07-18 1991-08-06 E. I. Du Pont De Nemours And Company Pseudorabies virus recombinants and their use in the production of proteins
NZ230425A (en) * 1988-09-02 1992-07-28 Molecular Eng Ass Production of paramyxovirus fusion (f) protein using recombinant baculovirus expression vector

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017589A1 (es) * 1991-03-26 1992-10-15 Ercros S.A. Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino
WO1992017205A1 (es) * 1991-03-26 1992-10-15 Ercros S.A. Procedimiento para la produccion de una vacuna subunidad contra el parvovirus canino y otros virus relacionados
EP0508809A1 (de) * 1991-04-10 1992-10-14 British Bio-Technology Limited Fett enthaltende proteinhaltige Partikel
WO1992019267A1 (en) * 1991-05-08 1992-11-12 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOTTET, G. ET AL.: "Intracellular stability of nonreplicating paramyxovirus nucleocapsids", VIROLOGY, vol. 176, no. 1, May 1990 (1990-05-01), pages 1 - 7 *
See also references of WO9301833A1 *

Also Published As

Publication number Publication date
JPH06509228A (ja) 1994-10-20
EP0595970A1 (de) 1994-05-11
WO1993001833A1 (en) 1993-02-04
NZ243611A (en) 1993-12-23
CA2113572A1 (en) 1993-02-04

Similar Documents

Publication Publication Date Title
ZA922011B (en) Vaccine
ZA929335B (en) Device.
GR3025184T3 (en) Vaccine composition containing adjuvants.
ZA927562B (en) Medicament.
GB9106048D0 (en) Vaccines
DE59204008D1 (en) Trachealstent.
ZA926482B (en) Cyanophenylpyrroles.
EP0554456A4 (de) Faksimilepostvorrichtung.
ZA927792B (en) Anti-alpha6-integrin-antibodies.
GR3024994T3 (en) Lymphoid cd30-antigen.
EP0595970A4 (de) Verbesserter impfstoff.
ZA929590B (en) Diphenylsulphides.
ZA929294B (en) Syringe.
DE69205795D1 (en) Mesoprotheseunterlage.
EP0599077A3 (de) Anti-metastatischer Impfstoff.
EP0572573A4 (de) Aus schilddrüsen gewonnener chondrozyten-stimulierender faktor.
DE69203865D1 (en) Thermo-transferdrucksystem.
DE69204801D1 (en) Hydroxy- oder oxosubstituierte alkylcyclopentene.
ZA929820B (en) Heisswinderschieber.
ZA929331B (en) Quinolylmethoxyphenyl-acetamides.
ZA925725B (en) Qinolin-2-yl-methoxybenzylhydroxyureas.
EP0570462A4 (de) Abgeändertes interleukin-1beta.
ZA921865B (en) Isoxazole- and isothiazole-5-carboxamides.
DE59200703D1 (en) Polyketomethinfarbstoffe.
ZA939564B (en) Vaccines.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940211

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

RHK1 Main classification (correction)

Ipc: C12N 15/47

A4 Supplementary search report drawn up and despatched

Effective date: 19950407

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980203